Table 3 Unadjusted Cox proportional hazards models for recurrence.

From: Efficacy of artemether lumefantrine vs chloroquine for the treatment of Plasmodium Vivax infection in Pakistan

Follow-up Time

HR (95% CI), p-value

CQ vs. CQ + PQ

AL vs. AL + PQ

AL vs. CQ

AL + PQ vs. CQ + PQ

Day 28

Hazard ratio

4.66 (0.59–36.60), p = 0.143

3.42 (0.99–11.74), p = 0.051

2.68 (1.22–5.89), p = 0.014

5.28 (0.54–51.32), p = 0.152

End of Follow-Up

Hazard ratio

13.53 (1.78–102.88), p = 0.012

4.90 (1.88–12.81), p = 0.001

2.28 (1.19–4.39), p = 0.013

0.16 (0.02–1.35), p = 0.091

  1. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using unadjusted Cox proportional hazards models. HRs compare the hazard of recurrence in the first-listed regimen versus the second-listed regimen. Time to recurrence was defined as the interval from completion of antimalarial therapy to parasitologically confirmed Plasmodium vivax infection occurring ≥ 14 days after treatment. “End of follow-up” refers to the final observation window (approximately 6 months); participants without recurrence were censored at the date of last contact. No weighting or multivariable adjustment was applied.
  2. Abbreviations: CQ, chloroquine; AL, artemether–lumefantrine; PQ, primaquine.
Back to article page